



## M K PROTEINS

To,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Plot no. C/1,  
G Block, Bandra- Kurla Complex  
Bandra (E) Mumbai - 400 051.

Date: 13<sup>th</sup> November, 2021

**Sub: Intimation of outcome of Board Meeting of the Company held on 13<sup>th</sup> November, 2021 pursuant to Regulation 30 and 33 of SEBI (Listing Obligation & Disclosure Requirements), Regulations 2015.**

**REF: SYMBOL: MKPL, ISIN: INE964W01013**

Dear Sir/ Ma'am,


With regard to the above captioned subject, we are pleased to submit the Outcome of Board Meeting of the Company held today i.e. 13<sup>th</sup> November, 2021 (Commenced at 06:30 P.M. and concluded at 07:30 P.M) to consider and approve unaudited Financial Results for the Half Year ended 30<sup>th</sup> September, 2021 along with Auditors Limited Review Reports for the Half Year ended 30<sup>th</sup> September, 2021.

Please find enclosed herewith the approved "Un-Audited Financial Results" for the half year ended on 30<sup>th</sup> September 2021, under Clause 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 along with a copy of Limited Review Report.

Kindly acknowledge the receipt of the same.

Thanking You

Yours Faithfully,  
FOR M.K. PROTEINS LIMITED

  
Vinod Kumar  
Managing Director  
DIN: 00150507

---

**M. K. Proteins Ltd.**

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003  
T : 0171-2679358 | W: www.mkproteins.in | E: mkproteins1@gmail.com |  
CIN : L15500HR2012PLC046239

**M. K. PROTEINS LIMITED**  
**(Formerly Known as M. K. Proteins Private Limited)**

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

TIN: 06291043467 CIN: U15500HR2012PLC046239

Dated: 13<sup>th</sup> November, 2021

To,

The General Manager,  
Listing Department,  
NSE Limited-SME Platform  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400051

Ref: MKPL

Sub: Unaudited Standalone Financial Results for the half-year ended September 30, 2021

Sir,

We wish to inform you that the Board of Directors of the company has approved the unaudited standalone financial results for the half-year ended September 30, 2021 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") in their meeting held on 13<sup>th</sup> November, 2021. We enclose the following:


- Statement showing the unaudited standalone Financial Results for the half-year ended 30<sup>th</sup> September 2021.
- Independent Limited Review Report on unaudited Standalone Financial Results for the half-year ended 30<sup>th</sup> September 2021.

A copy of the same will be updated on the Company's Website.

Kindly take the information on record.

Thanking you,  
Yours faithfully,  
For M. K. Proteins Limited

(VINOD KUMAR)  
Managing Director  
DIN: 00150507



**M. K. PROTEINS LIMITED**  
(Formerly Known as M. K. Proteins Private Limited)

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003


T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

TIN: 06291043467 CIN: U15500HR2012PLC046239

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021**

	HALF YEAR ENDED			YEAR ENDED	
	30-09-2021	31-03-2021	30-09-2020	31-03-2021	31-03-2020
	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(AUDITED)
				(Rs. In Lacs)	
<b>1. Revenue</b>					
a) Net Sales/Income from Operations	11317.99	21204.70	9905.09	31109.79	19401.81
Other operating Revenue	0.00	0.00	0.00	0.00	10.45
Revenue from Operation (Net)	11317.99	21204.70	9905.09	31109.79	19412.26
b) Other Income	8.90	2.79	2.01	4.80	31.50
Sub-Total "1"	11326.89	21207.49	9907.10	31114.59	19443.76
<b>2. Expenditure</b>					
a) Cost of Material Consumed	6130.11	17529.74	4587.99	22117.73	16978.56
b) Purchase of Stock-in-Trade	3966.53	2700.96	2859.82	5560.78	1830.15
c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	33.35	(716.06)	1616.96	900.90	(808.94)
d) Employees Benefits Expenses	78.66	82.68	72.03	154.71	156.19
e) Manufacturing, Operating and Other Expenses	346.03	480.57	301.82	782.39	777.20
f) Finance Costs	26.61	50.42	24.56	74.98	149.18
g) Depreciation and Amortization Expenses	44.26	45.38	45.56	90.94	117.10
Sub-Total "2"	10625.55	20173.69	9508.74	29682.43	19199.44
<b>3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [ 1 - 2 ]</b>	701.34	1033.80	398.36	1432.16	244.32
<b>4 Exceptional Items</b>	0.00	0.00	0.00	0.00	0.00
<b>5 Profit/(Loss) before Extraordinary items and Tax [ 3 - 4 ]</b>	701.34	1033.80	398.36	1432.16	244.32
<b>6 Extraordinary Items</b>	0.00	0.00	0.00	0.00	0.00
<b>7 Profit/(Loss) before Tax [ 5 - 6 ]</b>	701.34	1033.80	398.36	1432.16	244.32
<b>8 Tax Expenses</b>					
a) Provision for Current Tax	180.36	297.95	104.37	402.32	74.74
b) Provision for Deferred Tax Liability/(Adjustment)	(3.80)	(4.94)	(4.11)	(9.05)	(12.11)
Sub-Total "8"	176.56	293.01	100.26	393.27	62.63
<b>9 Profit/(Loss) for the Period from continuing operations [ 7 - 8 ]</b>	524.78	740.79	298.10	1038.89	181.69
<b>10 Profit/(Loss) for the period from Discontinuing operations</b>	0.00	0.00	0.00	0.00	0.00
<b>11 Tax expenses of Discontinuing operations</b>	0.00	0.00	0.00	0.00	0.00
<b>12 Profit/(Loss) from Discontinuing operations (After Tax) [10 - 11]</b>	0.00	0.00	0.00	0.00	0.00
<b>13 Profit/(Loss) for the period [9 + 12]</b>	524.78	740.79	298.10	1038.89	181.69
<b>14 Earning Per Shares (EPS)</b>					
-Basic	12.58	17.76	7.15	24.91	4.36
-Diluted	12.58	17.76	7.15	24.91	4.36
<b>15 Paid-up Equity Shares Capital</b>					
4170800 (Previous year 2708800) Equity Shares (Face value of Share Rs.10/- each)	417.08	417.08	417.08	417.08	417.08
	(Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)
<b>16 Reserves excluding Revaluation Reserves</b>	3041.54	2516.76	1775.66	2516.76	1477.56

*Handwritten signature*



**Note:**

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13<sup>th</sup> November, 2021.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment as per AS-17.
4. The Company has taken into account all the possible impacts of COVID-19 in preparation of standalone financial statements, including but not limited to its assessment of, liquidity and going concern assumption and recoverable values of its financial and non-financial assets. The Company has carried out this assessment based on available internal and external sources of information up to the date of approval of standalone financial statements and believes that the impact of COVID-19 is not material to these financial statements and expects to recover the carrying amount of its assets. The impact of COVID-19 on the standalone financial statements may differ from that estimated as at the date of approval of these standalone financial statements owing to the nature and duration of COVID-19.
5. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30<sup>th</sup> September, 2021 is given as per Annexure "I" attached

**Place: Ambala**

**Dated: 13-11-2021**

For and on behalf of the board



(Vinod Kumar)  
Managing Director  
DIN: 00150507

**M. K. PROTEINS LIMITED**  
(Formerly Known as M. K. Proteins Private Limited)

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

TIN: 06291043467 CIN: U15500HR2012PLC046239

**ANNEXURE "1"**


**STATEMENT OF ASSETS AND LIABILITIES AS AT 30<sup>TH</sup> SEPTEMBER 2021 IS GIVEN BELOW:-**

	PARTICULARS	AS AT 30-09-2021 (UNAUDITED)	AS AT 30-09-2020 (UNAUDITED)	AS AT 31-03-2021 (AUDITED)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
1.	Shareholder's Funds			
	-Share Capital	417.08	417.08	417.08
	-Reserves and Surplus	3041.54	1775.66	2516.76
	Sub-Total - Shareholder's Funds	3458.62	2192.74	2933.84
2.	Non-Current Liabilities			
	-Long Term Borrowings	21.81	313.00	444.91
	-Deferred Tax Liabilities (Net)	0.00	0.00	0.00
	-Other Long Term Liabilities	0.00	0.00	0.00
	-Long Term Provisions	5.56	4.46	5.56
	Sub-Total - Non-Current Liabilities	27.37	317.46	450.47
3.	Current Liabilities			
	-Short Term Borrowings	0.00	10.83	2011.30
	-Trade Payables	743.74	482.52	804.20
	-Other Current Liabilities	131.10	239.24	133.19
	-Short Term Provisions	196.04	104.37	402.32
	Sub-Total - Current Liabilities	1070.88	836.96	3351.01
	<b>Total Equity And Liabilities</b>	<b>4556.87</b>	<b>3347.16</b>	<b>6735.32</b>
<b>B.</b>	<b>ASSETS</b>			
1.	Non-Current Assets			
	-Property, Plant and Equipment	257.46	289.74	245.11
	-Deferred Tax Assets (Net)	31.48	22.73	27.68
	-Long Term Loans and Advances	42.35	42.35	42.35
	-Other Non-Current Assets	0.00	0.17	0.00
	Sub-Total - Non-Current Assets	331.29	354.99	315.14
2.	Current Assets			
	-Current Investment	930.00	191.32	0.00
	-Inventories	989.80	167.60	3769.93
	-Trade Receivables	2165.32	2299.52	2065.36
	-Cash and Bank Balances	2.21	0.65	0.13
	-Short Term Loan and Advances	138.07	332.90	584.58
	-Other Current Assets	0.18	0.18	0.18
	Sub-Total - Current Assets	4225.58	2992.17	6420.18
	<b>Total Assets</b>	<b>4556.87</b>	<b>3347.16</b>	<b>6735.32</b>

Place: Ambala

Dated: 13-11-2021

For and on behalf of the board



(Vinod Kumar)  
Managing Director  
DIN: 00150507

# M. K. PROTEINS LIMITED

(Formerly Known as M. K. Proteins Private Limited)


Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

CIN: U15500HR2012PLC046239

## CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021

PARTICULARS	30/09/2021	30/09/2020	31/03/2021
	(Rs.)	(Rs.)	(Rs.)
<b>A. CASH INFLOW/(OUTFLOW) FROM OPERATING ACTIVITIES</b>			
Net Profit/(Loss) before tax	701.34	398.36	1432.16
<b>Adjustment for:-</b>			
-Depreciation	44.26	45.56	90.94
-Interest paid	26.61	24.56	74.98
-Provision for Doubtful debts	0.00	0.00	3.91
-Provision for Retirement Gratuity Benefit to Employees	0.00	0.00	1.10
-Preliminary Expenses Written off	0.00	0.00	0.18
-Interest Income	(1.59)	(0.69)	(0.69)
-Profit on sale of Mutual Fund Investment	(1.60)	(1.32)	(4.11)
-(Profit)/Loss on Sale of Assets	0.00	0.00	0.00
Operating profit before working capital changes	769.02	466.47	1598.47
<b>Adjustment for changes in working capital:-</b>			
-Increase/(decrease) in Trade and other Payables	(15.94)	92.43	256.17
-(Increase)/decrease in Trade Receivables	(99.96)	(1349.13)	(1118.89)
-(Increase)/decrease in Inventories	2780.13	3731.29	128.95
-(Increase)/decrease in Loans and Advances	350.03	45.25	(89.83)
<b>Cash generated from operations</b>	3783.28	2986.31	774.87
(i) Income Tax paid	(290.16)	(30.05)	(146.33)
(ii) Interest paid	(26.61)	(24.56)	(74.98)
(iii) Dividend paid	0.00	0.00	0.00
<b>Net Cash inflow/(outflow) from operating activities (A)</b>	<b>3466.51</b>	<b>2931.70</b>	<b>553.56</b>
<b>B. CASH INFLOW/(OUTFLOW) FROM INVESTING ACTIVITIES</b>			
-Sale Proceeds of fixed assets/Subsidy Received	0.00	0.00	0.00
-Sale Proceeds for Investment in Mutual Funds	1091.60	176.32	369.11
-Increase in Tangible and Intangible Assets (Including Capital work-in-progress)	(56.62)	(25.15)	(25.90)
-Investment in Mutual Funds and others	(2020.00)	(366.32)	(365.00)
-Sundry Creditors for Capital goods	0.00	0.00	0.00
-Interest Income	1.59	0.69	0.69
-(Increase)/decrease in Long Term Advances & Other Non Current Assets	0.00	0.00	0.00
<b>Net Cash Inflow/(Outflow) from investing activities (B)</b>	<b>(983.43)</b>	<b>(214.46)</b>	<b>(21.10)</b>




**C. CASH INFLOW/(OUTFLOW) FROM FINANCING ACTIVITIES**

-Increase/(decrease) in short term bank borrowings (i.e. cash credit and overdraft facilities)	(2011.30)	(2633.64)	(633.17)
-Proceeds from long/short term bank and other Long term funds	34.47	0.00	500.52
-Repayment of Long Term Fund (Tem Loans and other Unsecured Loans)	(504.17)	(94.43)	(411.16)
-Proceeds from issue of share capital	0.00	0.00	0.00
<b>Net Cash inflow/(outflow) from financing activities (C)</b>	<b>(2481.00)</b>	<b>(2728.07)</b>	<b>(543.81)</b>
Net Cash flow during the year (A+B+C)	2.08	(10.83)	(11.35)
Cash and Cash Equivalent (Opening Balance)	0.13	11.48	11.48
Cash and Cash Equivalent (Closing Balance)	2.21	0.65	0.13


Place: Ambala

Dated: 13-11-2021

For and on behalf of the board



(Vinod Kumar)  
Managing Director  
DIN: 00150507



JAYANT BANSAL & CO.  
Chartered Accountants

Off.: 320, Mahesh Nagar,  
Ambala Cantt. - 133 001  
Phone: 2642401 (Off.)  
2661320 (Resi.)

Limited Review Report on unaudited Standalone Half Yearly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To,  
The Board of Directors,  
M. K. Proteins Limited  
Naraingarh Road, Village Garnala,  
Ambala City (Haryana), India - 134003

Ref: Limited Review Report of unaudited Standalone Financial Results for the half year ended 30<sup>th</sup> September, 2021

1. We have reviewed the accompanying statement of unaudited half yearly standalone financial results of M. K. Proteins Limited (Formerly Known as M. K. Proteins Private Limited) ("the Company") for the half year ended September 30, 2021, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These half yearly standalone financial results have been prepared on the basis of the standalone financial statement for the half year ended September 30, 2021, which are the responsibility of the Company's management and have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, and the relevant requirements of the Regulations and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited half yearly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Emphasis of Other Matters**

We draw attention to Note 4 of the standalone financial results, as regards the management's evaluation of COVID-19 impact on the business operations and carrying amounts of financial and non-financial assets of the Company. Our opinion is not modified in respect of this matter.

Place: Ambala Cantt

Date: 13/11/2021



For Jayant Bansal & Co.,  
Chartered Accountants  
Firm Regd. No. 004694N

JAYANT BANSAL  
M. No. 086478  
(PARTNER)

UDIN: 21086478AAAADR5739

